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Abstract
Islet transplantation can eliminate severe hypoglycemia symptoms caused by conven-
tional treatment, and has the advantages of less trauma and complications, which is con-
sidered as the most promising treatment for type 1 diabetes mellitus (T1DM). Regulatory 
guidance is needed for a standard pig source. In section 1, the regulation of medical grade 
designed pathogen free (DPF) donor pig for clinical xenotransplantation consists of five 
parts: genetic quality control, microbiological surveillance, formula feeds, specification 
of pathological diagnosis, and requirements of environment and housing facilities. In 
section 2, we present the current approach and progress in pig donor selecting, pancre-
atic digestion, isolation and preparation of porcine islet grafts, identification and quality 
assessment of final islet product in clinical trials. The liver is currently the most preferred 
site for islet transplantation, even though it is far from ideal. A large number of alter-
native sites have been used for islet transplantation in experimental animal models to 
provide improved engraftment and long-term survival. In Section 3, we introduce some 
commonly used sites in xenotransplantation. The benefits and drawbacks of each param-
eter above are discussed in an attempt to decide which is the most suitable for clinical use 
and to direct future research.
Keywords: cell and tissue xenotransplantation, clinical study, designated pathogen free 
status, islet xenotransplantation, regulatory guidance of source pigs, islets preparation, 
release criteria, sites for islet transplantation
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1. Regulation of medical grade designed pathogen free (DPF) donor pig 
for clinical xenotransplantation
Definition of PDF donor pig: the donor pig should be artificially bred and cultivated, genetic 
background or origin clear. The weight should not be more than 50 kg when 12-month old; 
WHO designated animal donor as pathogen free; pathogen infection must be prevented by 
biological safety barrier, antibiotics or vaccines free, for medical xenotransplantation, scien-
tific research, teaching, production, verification, as well as other scientific experiment [1].
Part 1: Genetic quality control
In this section, the genetic classification, breeding methods, and the genetic quality criteria of 
inbred herd and closed herd have been discussed, which are suitable for the genetic quality 
control of DPF medical donor pigs [2].
 1. Genetic classification and nomenclature
 1.1. Genetic classification: According to different genetic characteristics, DPF pigs are 
divided into inbred herd and closed herd.
 1.2. Nomenclature
 1.2.1. Nomenclature of DPF pigs
Herd, generally named after the capital English letters, can also use capital English letters 
and Arabic numerals; named symbols should be short as far as possible, such as XENO.
 1.2.2. Generation
The generation of herd use F in capital English letters. For example, an inbred herd for 
30 generations is written as F30.
 2. Breeding, including the principle of breeding, introduction, and methods
 2.1. Breeding of inbred herd
 2.1.1. Principle of propagation
Keep the inbred herd miniature pigs alleles homozygosity.
 2.1.2. Introduction
Breeding pigs of inbred herd medical grade xenotransplantation DPF donor pigs 
should be from foundation herd or pedigree expansion herd, the basis of genetic back-
ground is clear, complete data (including the name of the herd, inbreeding generation, 
genetic characteristics, and main biological characteristics).
 2.1.3. Methods
Inbred herd can be divided into foundation herd, pedigree expansion herd, and pro-
duction herd. When the production supply of the inbred herd miniature pig is not 
very large, generally no consanguinity expanding herd, just set foundation herd and 
production herd.
 2.2. Breeding of closed herd
 2.2.1. Principle of breeding
Keep the genetic heterogeneity and genetic polymorphism of closed herd miniature 
pig, avoid generation growth too fast.
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 2.2.2. Introduction
Breeding pigs of inbred herd medical grade should be defined genetic background or 
source is clear, complete data (Including the species-group name, origin, genetic charac-
teristics and main biological characteristics, etc.)
According to the way of breeding, ensuring the inbreeding generation growth in each 
generation under the premise of not greater than 1%, determines the minimal introduc-
tion scale. If using cycle copulation, introduction amount shall not be less than 13 pairs 
of unrelated pigs (within three generations, no common ancestor); if using random 
mating, introduction amount shall not be less than 25 pairs of unrelated pigs.
 2.2.3. Methods
Keep a closed herd of medical grade xenotransplantation DPF donor pigs genetic sta-
bility, and try to avoid inbreeding.
 3. The genetic quality monitoring of DPF medical donor pig
 3.1. Inbred herd
 3.1.1. Detection method
Microsatellite DNA markers detection method is generally used.
 3.1.2. Sampling
In foundation herd, all animal breeding parents should be tested. In production herd, 
a random sample from each inbred herd, half male and half female, should be tested.
 3.1.3. Result determination
All the alleles of microsatellite DNA markers in sample should conform to the charac-
teristic of the herd, no new alleles appear as qualified medical grade xenotransplanta-
tion DPF donor pigs inbred herd, otherwise the sentence to unqualified.
 3.1.4. Detection frequency
Genetic quality of medical grade xenotransplantation DPF donor pigs production herd 
should be tested at least once a year.
 3.2. Closed herd
 3.2.1. Detection method
Detection method is same as that of inbred herd.
 3.2.2. Sampling
A random sample from each inbred herd, half males and half females, should be tested.
 3.2.3. Result determination
The evaluation method of the genetic variation of the group is an average heterozygos-
ity index or group balance state.
When the average heterozygosity lies between 0.5 and 0.7, and no obvious difference 
was found between observed heterozygosity and expected heterozygosity by chi-
square test, the medical grade xenotransplantation DPF donor pigs can be qualified 
for closed herd. Or determine by whether the group is in a balance state, if there is 
no balanced, indicate that the gene frequency and genotype frequency of population 
changed, the closed herd of medical grade xenotransplantation DPF donor pigs group 
is not qualified.
 3.2.4. Detection frequency
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Genetic quality of closed herd medical grade xenotransplantation DPF donor pigs pro-
duction herd should be tested at least once a year.
Part 2: Microbiological surveillance
In this section, microbiology classification of pathogens, surveillance standard, proce-
dures, methods, rules, results determination, conclusions, sample preservation for xeno-
transplantation medical grade DPF donor pigs microbiology surveillance [1, 3–5] have 
been discussed.
Type Number Testing items
Bacterium 1 Brucella spp.
2 Leptospira spp.
3 Serpulina hyodysenteriae
4 Mycobacterium bovis
5 Mycobacterium tuberculosis
6 Mycobacterium avium-intracellulare 
complex
7 Mycoplasma hyopneumoniae
8 Salmonella typhi
9 Shigella
10 Bordetella bronchiseptica
11 Pasteurella multocida
12 Actinobacillus pleuropneumoniae
13 Streptococcus suis type 2
Fungi 14 Pathogenic dermal fungi
15 Cryptococcus neoformans
16 Histoplasma capsulatum
Parasites 17 Ectozoa
18 Ascaris suum
19 Echinococcus sp.
20 Isospora sp.
21 Strongyloides ransomi
22 Toxoplasma gondii
23 Trichinella spiralis
24 Neospora
25 Fasciolopsis buski
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 1. Microbiology classification: conventional (CV) minipig, clean (CL) minipig, specific 
pathogen free (SPF) minipig
 2. Microbiological surveillance standard
 2.1. Clinical observation
A visual inspection without abnormality has been done.
 2.2. Microbiological testing items
Details see Table 1.
 2.3. Microbiological testing procedures
Numbering—visual inspection—Blood sampling—Testing—Result determination.
 2.4. Sample testing frequency
Testing is done at least once in every 6 months.
 2.5. Sampling standard
Choose the  pig which is more than 6-month-old for detection. random sampling.
 3. Results determination
Results determination is according to the various microbial detection items. For anti-
body testing item, serum antibody negative is qualified.  For antigen and nucleic acid 
testing item,  no positive is qualified.
Type Number Testing items
Viruses 26 Adenovirus (porcine)
27 Encephalomyocarditis virus
28 Porcine influenza virus
29 Human influenza viruses
30 Porcine cytomegalovirus
31 Porcine gammaherpesvirus
32 Porcine reproductive and respiratory 
syndrome virus
33 Porcine parvovirus
34 Rotavirus
35 Pseudorabies virus
36 Rabies virus
37 Foot and mouth disease virus
38 Classical swine fever virus
39 Japanese encephalitis virus
40 Porcine circovirus type 2
41 Porcine transmissible gastroenteritis 
virus
42 Swine vesicular disease virus
Table 1. Microbiological testing items [3].
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 4. Preservation standard for microbiology testing sample
Sample data, sample source, animal numbering, sample type and number, save by 
medical pathology data file management standard. Save time for 1 year.
Part 3: Formula feeds
Raw material for feed, nutrition, feed production, sanitary standard for medical grade xeno-
transplantation DPF donor pigs quality control of feed [6].
 1. Raw material for feed
 1.1. Principle of selection
Raw material should be certified as green food, or from the product of standard green 
food production base. Or from self-production green food which is qualified by gov-
ernment. According to the mode of green food production standard.
 1.2. Nutrition
Details see Table 2.
 1.3. Product requirements
 1.3.1. Sense
The color should be homogeneous, without mildew, caking and odor.
 1.3.2. Water
Compound feed 13.5% or less.
 1.3.3. Mixing homogeneity
Compound feed, concentrated feed mixing uniformity coefficient of variation (CV) of 
7% or less; Additive premixed feed coefficient of variation (CV) of 5% or less.
 1.4. Sanitary requirement
Shall conform to the World Health Organization (World Health Organization, WHO) for 
medical donor animal food hygiene requirements, within the sterilization period of validity.
Item Standard Growth and reproduction feed
sustaining feed
Water, % ≤ 11.0 11.0
Crude protein, % ≥ 12.0 14.0
Crude fat, % ≥ 2.5 3.0
Crude fiber, % ≤ 7.5 7.0
Crude ash, % ≤ 8.0 7.5
Calcium, % 0.65–1.0 0.75–1.0
Phosphorus, % 0.55–0.7 0.58–0.8
Available phosphate, % 0.32–0.4 0.32–0.4
*Modified from Laboratory animal wuzhishan pig, Feed nutrients requirements. (http://down.foodmate.net/standard/
sort/15/42411.html. In Chinese).
Table 2. Feed nutrition ingredient detection index*.
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Part 4: Specification of pathological diagnosis
In this section, the contents and methods of pathological examination for medical grade xeno-
transplantation DPF donor pigs, including examination rules, procedures, clinical pathology, 
anatomy and results determination and conclusion have been discussed [2, 7, 8].
 1. The frequency of examination, sampling requirements, sampling methods, and the 
number of samples
 1.1. Examination frequency
Clinical pathology inspection check should be done at least once in every 6 months; 
anatomical pathology testing check should be done at least once in every 2 years.
 1.2. Sampling requirements
 1.2.1. Method
Select 6 months above medical grade xenotransplantation DPF donor pigs for detecting 
random sampling.
 2. Clinical and pathological examination
 2.1. Visual examination
Mental state, coat, skin, natural orifice, nutritional status, motions, eating, breathing, etc.
 2.2. Hematology detection
RBC: Red Blood Cell, HCT: Hematocrit, MCV: Mean Corpuscular Volume, HGB: 
Hemoglobin, MCH: Mean Corpuscular Hemoglobin, MCHC: Mean Corpuscular 
Hemoglobin Concentration, RDW: Red Cell Distribution Width, PLT: Platelets, MPV: 
Mean Platelet Volume, WBC: White Blood Cell.
 2.3. Biochemistry detection
ALT: Alanine Aminotransferase, AST: Aspartate Amino Transferase, Scr:Serum 
Creatinine, BUN: Blood Urea Nitrogen, TP: Total Protein, ALB: Albumin, GLU: Glucose, 
T-BIL: Total Bilrubin, TG: Triglyceride, T-CHO: Total cholesterol.
 2.4. Autopsy and pathological examination
 2.4.1. Surface: the developmental status, nutritional status, mental state, sense organs, respi-
ratory system, coat, skin, and testicles.
 2.4.2. Subcutaneous: fat, mammary gland, lymph nodes (lymph nodes under the jaw, neck 
shallow lymph node, axillary lymph nodes, popliteal lymph nodes), and epididymis.
 2.4.3. Head and neck: oral, nasal, brain, cerebellum, brainstem, pituitary gland, tonsil, thy-
roid, parathyroid gland.
 2.4.4. Chest: pleural fluid, the thymus, the lungs and the lung, pericardium, pericardial fluid 
lymph node and the heart, the aorta, trachea, and bronchi.
 2.4.5. Abdominal cavity: peritoneal fluid, spleen and lymph nodes, liver, gallbladder, liver 
door parts of the blood vessels, bile duct and lymph nodes, pancreas, kidney, adrenal, 
stomach, intestines, duodenum, jejunum, ileum, caecum, colon, rectum) and mesen-
teric lymph nodes.
 2.4.6. Pelvic: bladder, ureter, prostate, seminal vesicle, ovaries, fallopian tubes, uterus, vagina.
 2.5. Histopathological examination
Heart, lung, liver, spleen, kidney, stomach, jejunum, mesenteric lymph nodes, ovary/
testis, and gross anatomy examination revealed abnormal organs and tissues.
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 3. Results determination
Clinical pathology examination result is divided into four levels: did not see abnormal-
ity, minor abnormality, mild abnormality, and obvious abnormality. The pathologi-
cal diseases are divided into congenital and infectious diseases, no matter what level, 
noninfectious disease excluded disease individuals, the whole group is ruled out when 
infectious disease occurs.
 3.1. No abnormality: animal appearance without abnormality, at the same time, the blood 
test indices in the normal reference value range.
 3.2. Minor abnormality: animals have no obvious abnormal appearance, but blood tests 
index one or two higher or lower, the biggest variation is not more than 20% of the 
normal reference value range threshold.
 3.3. Mild abnormality
 3.3.1. No obvious abnormal animal appearance, but more than two blood tests index higher 
or lower, the biggest variation is 20–50% of the normal reference value range threshold.
 3.3.2. Mildly abnormal appearance, at the same time more than two blood tests index 
higher or lower, the biggest variation is 20–50% of the normal reference value range 
threshold.
 3.4. Obvious anomaly
 3.4.1. No obvious abnormal animal appearance, but more than two blood tests index higher 
or lower, the biggest variation is more than 50% of the normal reference value range 
threshold.
 3.4.2. Animal mildly abnormal appearance, at the same time more than two blood tests index 
higher or lower, the biggest variation is more than 50% of the normal reference value 
range threshold.
 3.4.3. Animal appearance is apparently abnormal
Part 5: Requirements of environment and housing facilities
In this section, the requirements of facilities, environmental conditions and drinking water, 
cushion, cage and transport standard for medical grade xenotransplantation DPF donor pigs 
[2, 8–11] have been discussed.
 1. Construction
 1.1. Building site
 1.1.1. Chooses a good air quality and natural environment
 1.1.2. Should be far away from the urban residential area and places have serious air pol-
lution, vibration or noise of railway, docks, airports, roads, factories, storage, storage 
area, slaughtered live herd and poultry farms, factories, etc.
 1.1.3. Facilities should be reliable to avoid other animal feeding cross infection
 1.2. Sanitary requirements
 1.2.1. External environment should be clean and tidy, easy to clean, and disinfectant. Drainage 
should be unblocked, without waste and sewage accumulation.
 1.2.2. Set entrance for people, animals, objects, vehicles is dedicated, special disinfection facil-
ities and equipment.
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 1.2.3. There should be measures to prevent exotic animals in and the experimental animals 
out.
 1.2.4. Structure of the barrier should be solid, nontoxic, and without any radioactive 
material.
 1.3. Facilities requirements
 1.3.1. Doors and windows of the building should have good sealing; the observation win-
dow should be set up in the feeding door, set appropriate buffer room door interlock 
device.
 1.3.2. Air-tight door of barrier environment facilities should be open in the direction of the 
higher air pressure, and can be automatically shut down.
 1.3.3. The stairs width should not be less than 1.2 m; the corridor width generally should 
not be less than 1.5 m. The slot width should not be less than 1.0 m. The door width 
should meet the requirements for equipment to be in and out, width of which should 
not be less than 0.8 m.
 1.3.4. Barrier environment facilities should be according to the need to maintain the correct 
pressure direction.
 1.3.5. Breeding should be a reasonable organization between the location of the outlet and 
the inlet air flow, avoid blind angle and short circuit.
 1.3.6. The pipe orifice of clean areas toward nonclean areas  should be sealed. Drains, tank, 
pipe slope should guarantee the smooth drainage with no dirt accumulation. Drainage 
pipe diameter should not less than DN150.
 1.3.7. There should be an established environmental monitoring system and the level of 
other facilities according to the need to set up the environment monitoring system.
 1.4. Construction requirements
 1.4.1. Passageway of goods should set up a ramp or unloading platform. The ramp slope 
should not be more than 1/10.
 1.4.2. Rooms with the drain, drainage slope should not be less than 1%; the ground should 
be tested for waterproof processing.
 1.4.3. Animal feeding room and lab should be set separately.
 1.4.4. The autoclave sterilization equipment should be set between cleaning and disinfec-
tion room and clean storage room.
 1.4.5. Production area (lab area); the height should not be less than 4.2 m.
 1.4.6. The surface of Windows and doors, walls, ceiling, floor (ground) surface in clean area 
should be smooth, the structure and construction cracks reliably airtight measures 
should be adopted, metope and ground intersect position should have a radius of not 
less than 30 mm arc processing.
 1.5. Water supply and drainage requirements
 1.5.1. Water supply
1. 5.1.1. The area of water purification should meet the requirements of sterilization.
1. 5.1.2. Water supply system in production area (lab area) should be well equipped with the 
technology layer.
1. 5.1.3. Purification pipeline crossing the wall, reliably sealing measures should be taken.
1. 5.1.4. Water supply pipe and pipe fittings of purification area should be of corrosion resis-
tance and provided with convenient and reliable connections.
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 1.5.2. Drainage
1. 5.2.1. The septic tank must be individually set up for the drainage of production and lab 
area.
1. 5.2.2. Drainage in barrier environment facilities should be set apart from subsistence 
drainage.
1. 5.2.3. Purification area should not be through the drainage riser.
1. 5.2.4. Pipes should be rust and corrosion free.
1. 5.2.5. The drain floor of purification area should be airtight.
 2. Layout
 2.1. Overall layout
 2.1.1. According to DPF medical donor pig’s physiological needs and behavior characteris-
tics, design and built their living facilities, and to strictly control the in and out of the 
personnel, goods, animals and the air.
 2.1.2. Production area includes quarantine inspection room, the buffer room, shower rooms, 
corridors, clean storeroom, post disinfection room and board, mating, pregnancy, 
childbirth, breastfeeding, piglets, breeding pig house, etc.
 2.1.3. Lab area includes buffer room, animals bath room, clean storeroom, post disinfec-
tion room, corridors, quarantine inspection room, preparation room, operating room, 
postoperative observation room, breeding room, etc.
 2.2. Requirements for the main locale
 2.2.1. Breeding room setup requirements
2. 2.1.1. Water system should prevent reflux and alien species.
2. 2.1.2. Breeding room should be equipped with appropriate feeding equipment and capture 
tools. Equipment and tools shall ensure to be firm and will not harm the animal.
 2.2.2. Operating room setup requirements
2. 2.2.1. Should set up comprehensive laboratory, equipped with necessary equipment and 
according to the demand.
2. 2.2.2. Should set up isolation room to independently observe injured and suspected dis-
eased animals.
2. 2.2.3. Should set up quarantine room for new animals.
2. 2.2.4. According to the need to set up postoperative observation room.
 2.2.3. The auxiliary area setup requirements
2. 2.3.1. Environmental controls should be strict in the feed storeroom, preventing pathogenic 
microorganism pollution, parasites pollution, and alien species.
2. 2.3.2. Should set up storeroom with storage cages and instruments.
2. 2.3.3. Disinfection room space should be accessible for cleaning process. Before and after 
cleaning equipment should be placed separately. The walls and floor waterproof 
treatment should be done.
2. 2.3.4. Specialized room and (or) equipment should be set up for animal bodies and waste 
storage
2. 2.3.5. Should set up the observation corridor, or observation area, or set up a video surveil-
lance system, used for observing animals.
 3. Feeding conditions
 3.1. Fence
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 3.1.1. Choose a material that is nontoxic, washable, high temperature resistant, and easy to 
sterilize.
 3.1.2. Bar size should meet the miniature pig lying down, feed intake and defecation, or use 
the fence to establish different function areas. Fences should be strong.
 3.2. Manger
 3.2.1. Choose a material that is nontoxic, washable, high temperature resistant, and easy to 
sterilize.
 3.2.2. The size of the manger should allow all the animals to eat at the same time.
 4. Environment
Details see Table 3.
 5. Waste disposal
 5.1. Sewage
Primary sewage treatment equipment or anaerobic tank should be equipped.
 5.2. General waste
Waste packing should be gathered for disposal. Disposable coverall, masks, hats, 
gloves, and experiment of waste should be treated harmless. Injection needles, razor 
blades sharp items should be collected in toolbox processed by corresponding quali-
fications organization.
 5.3. Infectious waste
Infectious waste must be high pressure sterilized before processing.
Item Index
Temperature, °C 20–26
Daily temperature difference, °C, ≤ 4
Relative humidity, % 40–80
Pressure gradient in the same area, Pa, ≥ 10
Air velocity, m/second, ≤ 0.2
ventilation rate, /hour, ≥ 15
Air cleanliness, level 7
Mean concentration of settled bacteria/0.5 hours/Φ 90 mm plating, ≤ 3
Detection rate of designed pathogen, %, ≤ 0
Ammonia concentration, mg/m3, ≤ 14
Noise, dB(A), ≤ 60
Illuminance,lx Working, ≥ 200
Animal 100–200
Photoperiod, hour 12–14/12–10
*Modified from Laboratory animal wuzhishan pig, Feed nutrients requirements. (http://down.foodmate.net/standard/
sort/15/42411.html. In Chinese.)
Table 3. Environment factor index*.
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 5.4. Animal waste
Animal bodies and tissues should be loaded in special bags stored in the refrigerator or 
freezer, gathered for harmless disposal.
 6. Transport
 6.1. Transport cages
 6.1.1. Should be strong and can prevent animal damage and escape, have feces and urine 
collection device, and in accordance with the requirements of the animal health and 
welfare. Suitable for carrying, is conducive to protect animals, and handling personnel 
safety.
 6.1.2. In accordance with the corresponding microbial control environment, easy to clean, 
and disinfectant.
 6.1.3. With peripheral filter membrane, internal solid cages of biological security isolation 
function.
 6.2. Transportation
 6.2.1. The transportation shall be equipped with air conditioning and other equipment and 
able to keep the environment temperature stable.
 6.2.2. It should be able to ensure that there is enough fresh air and the shipping space of the 
cages, meets the needs of the animals’ health, safety, and comfort.
 6.2.3. The transportation can be disinfected.
 6.2.4. Long-distance transportation (more than 6 hours) should provide drinking water, feed 
whenever necessary.
Conclusion
In conclusion, after strict genetic quality control, close monitoring of pig breeding condition 
and process, and extensive microbiological screening, we have selected a DPF herd as donors 
for cell xenotransplantation. This herd is free from all tested conventional and xenotrans-
plantation related pathogens. It can not only minimize microbial negative impact, but also be 
likely to reduce swine pathogen infection risk, which will promote the development of clini-
cal xenotransplantation from pig donor sources.
Isolation, purification, and quality control of islet in clinical porcine 
islet xenotransplantation
Islet cells are mainly divided into three types according to different hormone secretion, 
namely glucagon secretion α-cells, insulin secretion β-cells, and somatostatin secretion δ-cells. 
β-cells can regulate insulin release by sensing the change of glucose level in order to maintain 
euglycemia. Islet transplantation can eliminate severe hypoglycemia symptoms caused by 
conventional treatment and has the advantages of less trauma and complications, which is 
considered as the most promising treatment for type 1 diabetes mellitus (T1DM). In recent 
years, with the maturing of islet cell transplantation technology and the development of the 
clinical application, pancreatic islet transplantation has gradually showed satisfactory and 
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prospective approach in the treatment of T1DM. Nonetheless, the donors’ shortage still pre-
cluded the development and progression of clinical islet transplantation. Xenotransplantation 
offers an effective and feasible solution for this limitation. Among many potential candidates, 
pig is considered as the most ideal donor for future clinical applications. Although a number 
of encouraging findings have been reported in preclinical trails, the clinically pervasive appli-
cation of pig islet xenotransplantation still faces the challenges such as inadequate supply of 
islet cells with high-quality. This section will discuss the current approach and progress in pig 
donor selecting, isolation, and preparation of porcine islet grafts, quality control, and release 
criteria of final product in clinical trials.
 1. Selection of islet from different sources of donor pig
 1.1. Comparison of characteristics of newborn pigs, young pigs, and adult pigs
Islets may be harvested from newborn (neonatal), young, or adult pigs for transplantation 
into human in clinical trials. For human recipients, pig donor sources not only comply 
with the regulation of medical grade DPF donor pig for clinical xenotransplantation, but 
also must conform to human islets in terms of structure and function to regulate the high 
blood glucose level found in T1DM patients. Despite several years of investigation, no real 
consensus has been established with regard to the best pig strain to provide enough viable 
and functional isolated porcine islets for xenotransplantation [12].
Newborn or neonatal (aged 1–5 days) islet-like cell clusters, (NICCs) have several 
advantages as the preferred source of β-cells for xenotransplantation. Compared to 
young or adult pig islets, they can be procured and are easy to isolate by enzymatic 
digestion [13–15] and there is less batch-to-batch variation between isolations. The 
main problem with NICCs is the need to culture for maturation to achieve functional-
ity, which is as a potential source of cells because they have an inherent ability to pro-
liferate and differentiate in vivo [16]. The NICCs are composed of fully differentiated 
endocrine cells (35%) and endocrine precursor cells (57%) [17].
Reducing warm ischemia time in the surgical procedure is indispensable for processing 
of pancreases from young or juvenile (12–15 weeks) pigs. However, culturing between 
weeks 5 and 24 is required for further maturing of the islets acquired from young pigs, 
which is unpractical for clinical transplantation owing to isolation difficulties and 
immature capability [17, 18].
Isolation and purification of islets acquired from adult pigs (>2 years) is still demand-
ing to conduct and repeat, although there were many experiences in this field pre-
viously. The mature islets from adult pigs are physiologically similar to humans, 
which can secrete insulin in response to a glucose challenge. However, adult pig 
islets require mature pigs of more than 2 years of age [19], furthermore, the logistical 
considerations of keeping and handling large numbers of adult donor pigs in spe-
cific pathogen free housing for this period is impractical, which are not present with 
neonatal or juvenile pigs.
Dufrane D’s group reported a protocol providing a greater than 90% chance to obtain a 
sufficient islet yield for adult pig islet xenotransplantation into no human primates [20]. 
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Furthermore, they demonstrated that the β-cell percentage within islets is significantly 
affected by pig age (87.0 ± 3.3% versus 82.1 ± 3.6% for young and adult pig donors, 
respectively) [21]. This was directly correlated with a significant difference in non–β-
cell composition between islets from young and adult pig donors (11.8 ± 3.3% versus 
16.2 ± 3.4%, respectively).
 1.2. Comparison of different methods for isolation and purification of islets of newborn 
pigs, young pigs, and adult pigs
 1.2.1. NICC isolation
Once removed, the pancreata of neonatal pigs were finely chopped and digested with 
collagenase Type V, 1 mg/ml (Sigma-Aldrich) at 37°C. The digested tissue was washed 
in Hank’s balanced salt solution (HBSS) (Gibco) and filtered through a 500-μm sieve. 
Tissue was plated into dishes (No tissue culture treated) with Hams F-10 medium 
(Gibco) containing 10 mM glucose, 50 mM isobutylmethylxanthine, 10% porcine 
serum, 2 mM L-glutamine, 10 mM nicotinamide, 100 U/ml penicillin, and 100 μg/ml 
 streptomycin, CaCl2 0.236 g/l, hepes 80 mM, NaHCO3 21.3%(Sigma-Aldrich), with full 
media changes every other day. The cells were cultured at 37°C and 5% CO
2
.
NICCs were isolated and cultured for up to 27 days postisolation. Number of islet 
equivalents (IEQ), viability, and function were analyzed each week to determine 
whether time in culture was important for NICC function in vivo. It is reported that 
culture of NICC for 12 days provided the best outcome of viability and function in vivo 
posttransplantation, which was revealed by better reversal of diabetes, and lower levels 
of TF expression and higher expression of insulin, glucagon, and Bcl-2 with acceptable 
cell loss in terms of time and expense [22].
 1.2.2. Islet isolation from young pigs
For young pigs, briefly, the pancreas was harvested using rapid surgical procurement 
(<5 min) and placed in organ preservation solution. Cold ischemia time was limited to 
less than 30 min. The pancreas was then washed in cold (4°C) HBSS supplemented with 
hepes and trimmed of surrounding adipose and lymphatic tissue in a sterile environ-
ment. The pancreatic tissue was then minced into 2–3 mm3 pieces and digested at 37°C 
using sigma type V collagenase (2.5 mg/mL in HBSS). The mean digestion time was 
around 16 min. The islet tissue clusters (50–500 μm) isolated using the method above 
were allowed to mature into complete islets during culture in vitro at 37°C, 5% CO
2
 at first 
in recovery maturation media (Optatio LLC) supplemented with 10% porcine serum, 
417 mM dornase α, 215 mM aprotinin, 0.5 mM pefabloc, and then in a novel maturation 
media (Optatio LLC) 48 hours later, supplemented with 10% porcine serum [23, 24].
 1.2.3. Islet isolation from adult pigs
The factors as follows influence the islet yield of pancreas from adult pigs: (1) pancreas 
acquisition (exsanguination and warm ischemia time), (2) the ingredient of cold stor-
age solutions, (3) the various methods of pancreas digestion and purification, and (4) 
the endotoxin content and enzymatic activity. Researchers concluded some variables 
through a variety of investigation, which could enhance the yield of islets, for example, 
the application of blood exsanguination before pancreas procurement, a warm isch-
emia time within 10 min, the concentration of <30 EU of endotoxin in Liberase batches, 
etc. To the contrary, the isolation technique (dynamic versus static) and the storage 
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method (short-term versus long-term) and solution (UW versus modified UW) did not 
obviously affect the islet yield. Additionally, there was a positive relationship between 
isolated islet number and the number of islets/cm2 or with the percentage of large islets 
shown by the pancreas biopsies. Pig pancreases containing more than 82 islets/cm2 and 
more than 42% of large islets (>100 μm); thus, enabled more than 120,000 islet equiva-
lents to be harvested in 90% of the cases [20].
 2. Methods for islet quality control
To ensure the safety and efficiency of islet transplantation, all kinds of measurements 
have been processed. The quality parameters of islet products involved sterility, purity, 
viability and activity, cell population, and functionality. It has been suggested that 
transplantation of poor quality islet product would cause the inconsistencies of the 
ability of islet transplants to reverse diabetes [25, 26], so islet quality control is critical 
to both determining the suitability of islets for transplantation as well as to maintain a 
long-term functional graft in recipients posttransplantation.
 2.1. Biological safety
As the main aim of clinical islet isolation is transplantation into a recipient, biological 
safety of the final product is an essential criterion for product release. This is particu-
larly significant as recipients are immunosuppressed and thus are at an increased risk 
that infectious pathogens enter the recipient as part of the transplant product and cause 
infectious disease [27].
To test for the microbial sterility, sample aliquots are taken from  the culture  medium 
post-purification and post-culture respectively. Two aliquots from each time point are 
inoculated aseptically into bactecTM culture vials (Becton Dickinson) specific for aero-
bic (tryptic soy broth) and anaerobic (soybean-casein digest broth) bacteria culture for 
72 hours [28, 29]. Furthermore, samples are also cultured for fungi, mycoplasma, and 
mycobacteria. At last, the final product is tested for a large series of viruses, consisting 
of more than 28 viruses.
Endotoxin contaminants are known to lead to islet cell damage and early graft loss. 
Additionally, microbial contamination is likely to occur at various stages throughout 
the islet isolation, purification, and culture procedure. The reagents and supplies are 
possible sources of endotoxins in islet preparations [30, 31], but the most likely source of 
contaminations is the donor duodenum during pancreas surgical retrieval, as observed 
from testing of the solution in which the sample of retrieved pancreas is preserved [32].
It is very crucial to determine the sterility of islet preparations for transplantation, and 
several measures are in place to reduce risk of contamination after isolation and cul-
ture. Antibiotics are usually supplied to culture media, and aliquots are taken for Gram 
staining, endotoxin content measurement, and microbiological culture both after isola-
tion and pretransplant after culturing. In terms of islets release, a negative Gram stain is 
required, as well as endotoxin content <5 endotoxin units (EU)/kg recipient weight [33]. 
Several studies have demonstrated that no clinical infection was observed in recipients 
and long-term graft survival remained unaffected by using these criteria [32].
 2.2. Biological characteristics
2.2.1. Quantity (islet equivalent determination, islet count standard)
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Islet count was determined by the number of islet equivalents (IEQ = conversion of 
actual number of islets into number of islets with a diameter of 150 μm) [34]. The 
final purity of islet products after purification was calculated as the ratio between 
islets (stained in red by dithizone) and exocrine tissue (unstained by dithizone) on an 
inverted phase contrast microscope with a calibrated grid in the eyepiece.
 2.2.2. Activity
Dithizone staining was also used to determine percentage of purity over the matura-
tion period. Islet viability was analyzed using Newport Green (NPG) (Invitrogen) 
and propidium iodide, imaged using fluorescence microscopy, and quantified with a 
microplate reader.
 2.2.3. β cell purity
 2.2.3.1. Flow cytometry
Newport Green (NPG PDX acetoxymethyl ether) binds to zinc present in β-cells. 
Apoptosis was measured by tetramethylrhodamine ethyl ester perchlorate (TMRE) 
selectively binding to mitochondrial membranes. 7-aminoactinomycin D (7-AAD) 
binds to DNA in dead cells as their membrane permeability is altered. NICCs were 
dispersed by accutase (Sigma-Aldrich) and then stained, respectively, with NPG, 
TMRE, and 7-AAD to determine the proportion of β-cells, viable cells, and dead cells. 
To obtain a numeric product, the β-cell viability index was calculated according to the 
following formula ((%βcells × %βcells viability)/10,000) [35].
2. 2.3.2. DNA content
Two samples of 200 IEQs of islets were obtained and stored at 20°C after washing 
with citrate buffer. Samples were sonicated and used to measure the DNA content 
using the Quant-iT Pico Green dsDNA Assay Kit (Invitrogen). Fluorescent excitations 
~480 nm, emission ~520 nm was used to read samples by staining with Pico Green 
fluorescent reagent.
2. 2.3.3. Insulin/DNA ratio
Cell suspensions of each sample were homogenized by ultrasonication on ice prior to 
detection of DNA content using a Quanti-iT Pico Green dsDNA Assay Kit (Invitrogen) 
and insulin content with an porcine insulin RIA kit (Biosource), respectively. Insulin 
capacity was obtained by the ratio of the insulin content to the DNA content in micro-
gram in 1000 NICC IEQ [25].
2. 2.3.4. Islet function identification
In vitro insulin capacity of the islet products was determined using glucose-stimu-
lated insulin release (GSIS). Eight hundred IEQ porcine islets were incubated in low 
glucose solution (2.8 mM) for 1 hour and then incubating half the cells in low glucose 
and half in high glucose (25 mmol/l) solution. The stimulation index was obtained 
as the ratio by dividing the average high glucose by the average low glucose value. 
Insulin levels were analyzed using a standard porcine insulin enzyme-linked immu-
nosorbent assay (Porcine Insulin ELISA; Mercodia), and absorbance was measured 
using a microplate reader [36].
Alternative cell functional assays to determine the metabolic activity such as 
ATP content and oxygen consumption rate can also be frequently used as release 
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criteria. These assays utilize small number of islets from the pooled product, 
and can be performed quickly prior to transplantation. Furthermore, they offer 
a good indication of the metabolic activity and potential functional capacity of 
the product. Finally, it should also include the reversal of diabetes in immune-
deficient mice relative to dose.
The FDA regulations place islets isolated for transplant therapy under the biologi-
cal products, requiring the released preparation to demonstrate product stability 
and consistency between lots in addition to complying with standards of product 
identity, safety, purity, and potency [37, 38]. The release criteria, formally, are based 
on porcine islet count per recipient weight (10,000–20,000 IEQ/kg for single trans-
plant), with purity greater than 30% (assessed using dithizone staining), viability 
greater than 70% (assessed using Newport Green/TMRE/7-AAD staining), endo-
toxin concentration <5 (EU) /kg recipient weight, and no detectable organisms in a 
Gram stain prior to transplantation, as well as to a glucose stimulation index (ratio 
of stimulated insulin secretion/basal insulin secretion) ≥1 [39, 40]. Criteria based 
on these are currently, in formal, applied at the institution for cell transplantation 
and gene therapy at the 3rd Xiangya Hospital of Central South University, China, 
where we require each islet preparation from neonatal pigs to reach the determined 
thresholds of islet number/mass, viability, purity, and sterility before the product is 
released for transplantation [41].
Conclusion
Based on the remarkable progress of islet cell transplantation technology in the experimental 
and clinical studies, the islet xenotransplantation from porcine donors expected to become 
one of the potential and fundamental treatments for type 1 diabetes mellitus. The effective 
separation and purification of functional pig islet for transplantation, has always been a 
hot research topic in the field of heterogeneous islet transplantation. With the continuous 
development of suitable sources of pig donors, modification of isolation and purification 
technology, the improvement of quality control system of islet products, how to establish 
simple, economic and standardized graft preparation, and evaluation standard as soon as 
possible will promote islet xenotransplantation technology make greater progress and enter 
the next step of clinical studies, which will benefit the patients with diabetes by the tangible 
therapy in the very near future. However, remaining questions and detailed problems need 
to be adequately addressed.
Current alternative sites for islet transplantation
A suitable transplantation site could accommodate a large volume of islets for transplantation 
in an ample space, which is very close to vasoganglion providing enough oxygen and nutrients 
in the course of revascularization. Furthermore, it should avoid the reduction of early islet 
from host immune and inflammatory responses, while if necessary, the site is accessible to 
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transplantation processes [42]. It is a priority of research to define extrahepatic engraftment 
sites. The purpose of ongoing studies is to find a microenvironment that could offer prompt 
transplantation and make the inflammation and islet cell death to a minimum at early stage. At 
the same time, it could realize continuous function, which is of particular interest for research-
ers. It has been demonstrated in experimental animal models that islet grafts transplantation 
with or without the strategy of bioengineering in a number of extrahepatic sites, even though 
translation in clinic for some is unclear [43–45]. Numerous sites have been proposed and tested, 
both experimentally and in some cases clinically, including the liver, kidney subcapsule, bone 
marrow, immune privileged sites, and peritoneum spaces. While some alternative sites may be 
advantageous in experimental models, their feasibility and translation into clinical settings is 
limited up to date. While it has been proved in clinic that the infusion of intraportal islet could 
abolish T1DM, there has been long a need for finding a selectable engraftment site to optimize 
clinical results in the long term. Experimental research has offered potential alternatives to 
repair normoglycemia, even though a number of methods have implied limitations in terms of 
technology and/or physiology.
Liver
Intrahepatic islet infusion via the portal vein accounts for all clinical islet transplants conducted 
worldwide. Percutaneous portal vein infusion under ultrasound and fluoroscopic guidance 
offers a minimally invasive procedure with the ability to regulate glycemic levels through 
portal insulin delivery [46]. Alternatively, in patients at risk for bleeding, the transplant is per-
formed by cannulation of a tributary of the portal vein using open surgery (minilaparotomy) or 
laparoscopic approach. It is worth noting the potential procedural risks such as portal throm-
bosis and bleeding [47]. A significant amount of intraportal islets are lost immediately after 
transplantation due to instant blood-mediated inflammatory reaction (IBMIR), which nega-
tively influences islet grafts through expression of tissue factor, resulting in platelet adherence, 
activation, clot formation, and lymphocyte recruitment. In addition, xenotransplantation has 
more severe obstructions than those of clinical islet allotransplantation because IBMIR is still a 
major obstacle for islet transplantation. In pig-to-NHP islet xenotransplantation, although the 
precise mechanisms are yet to be illuminated, simultaneous activation of complement, coagu-
lation, and platelets occurred immediately after monocyte and neutrophil infiltration, which 
play a pivotal role in this very early islet destruction. In order to solve this problem, a variety 
of genetically engineered pigs have been developed. The generalized strategies to introduce 
porcine genetic modification are knocking down or knocking out certain genes for polysac-
charide antigens, e.g., α-Gal, knocking in human complement regulatory proteins, coagulation 
and cellular immune response regulatory proteins, respectively, or combinations of the above 
genetic modifications. Technical speed development for genetically engineering modified pigs 
provides another approach to realize clinical islet xenotransplantation [48].
Peritoneum
The peritoneum has the advantages of accepting both unpurified and microencapsu-
lated islets as tested in many experimental studies. It is unfortunate that research in the 
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murine mode indicated that a great number of islets are made requests for hyperglycemia 
reversion, while the insufficiency of parasympathetic re-innervation of the transplant is 
related to abnormal glucose tolerance tests [49] and morphologic alteration in islet archi-
tecture [50]. In the nonobese diabetic mouse mode, intraperitoneal syngeneic islets micro-
encapsulated in 5% agarose hydrogel resisted to the autoimmune attack [51]. In terms 
of technique, a latest research suggested a minimally invasive laparoscopic process for 
microencapsulated islet autotransplantation in nonhuman primates [52]. As a result, the 
transplantation site was promptly applied in a successful clinical experiment [53] after the 
process of intraperitoneal alginate capsulated islets from neonatal pig was proved safe in 
the NHP mode [54].
Bone marrow
Bone marrow (BM) may represent an ideal microenvironment for islets, attribute to its pro-
tected and extravascular (but well vascularized) microenvironment, its broad distribution, 
and its easy access. Because of its broad distribution and easy access, BM has the poten-
tial to overcome not only the physiologic loss of islets, but also the technical limitations 
and complications encountered with the intraportal infusion [55]. A previous research 
reported that BM could provide an immunoprotected microenvironment that allogeneic, 
syngeneic, and xenogeneic islet could survive in nondiabetic rat models without immu-
nosuppression [56]. Based on this, an ongoing pilot clinical trial at San Raffaele Scientific 
Institute in Milan aims to evaluate the safety and feasibility of BM as a potential site for 
islet auto/allotransplantation. Some research results showed that the BM is a more suitable 
site than the liver for the implantation of islets in murine model [57]. However, further 
research is required to determine whether the results can be reproduced in large animals 
and eventually in humans.
Kidney capsule
The kidney capsule has been applied as a potential site for experimental islet transplants in 
murine models [58], despite its poor blood supply in a relative manner [59] and the fact that 
it does not supply an oxygen-rich microenvironment. Correspondingly, the surgical process 
in murine modes is easy, which lead to hyperglycemia reversion in several days. In addition, 
it has the advantages on  transplant restoration post-nephrectomy by both histologic research 
and function test on glucose metabolism. Compared with the number of liver, islets that could 
reverse chemically-induced diabetes were less when transplanted under kidney capsule in 
a syngeneic murine model of islet transplantation, mainly because the microenvironment 
for intraliver engraftment is less ideal [60]. In addition, a smaller islet mass is demanded to 
reverse hyperglycemia in the renal subcapsular space [61, 62]. Furthermore, islet transplants 
under the kidney capsule allow the cotransplantion with endothelial cells [63], MSCs [64], 
and BM stem cells [65]. In humans, the invasive surgical procedure is used to release the 
islets under the kidney capsule, which is the really limited space for a high transplant mass. 
Additionally, the diabetic nephropathy of recipients signifies the kidney capsule is not an 
ideal site for islet grafts [66].
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Conclusion
Although many implantation sites have been proposed, few have found their way into the 
clinical setting. The experts suggest that islets infusion into the liver through the portal vein 
has been the chief approach of option. Well characterized sites, e.g., the kidney capsule and 
other immunoprivileged sites, are significant experimental models but with some limitations 
in applicability in the clinical setting. Nevertheless, there is clinical potential for possible uti-
lization of both the peritoneum and bone marrow sites; however, further research is required 
before therapeutic advances can be made here.
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